Barrett's Oesophagus

Barrett's oesophagus
Ablative therapy for the treatment of Barrett's

oesophagus
Issued: August 2010
NICE clinical guideline 106
guidance.nice.org.uk/cg106
NICE has accredited the process used by the Centre for Clinical Practice at NICE to produce
guidelines. Accreditation is valid for 5 years from September 2009 and applies to guidelines produced
since April 2007 using the processes described in NICE's 'The guidelines manual' (2007, updated
2009). More information on accreditation can be viewed at www.nice.org.uk/accreditation
NICE 2010
Contents
Introduction .................................................................................................................................. 3
Patient-centred care ..................................................................................................................... 4
1 Guidance................................................................................................................................... 5
1.1 List of all recommendations .............................................................................................................. 5
2 Notes on the scope of the guidance.......................................................................................... 8
3 Implementation ......................................................................................................................... 9
4 Research recommendations ..................................................................................................... 10
4.1 Progression to dysplasia ................................................................................................................... 10
4.2 Markers of treatment success ........................................................................................................... 10
4.3 Effectiveness of treatment................................................................................................................. 11
4.4 Follow-up after treatment .................................................................................................................. 11
4.5 Information needs ............................................................................................................................. 12
5 Other versions of this guideline ................................................................................................. 13
5.1 Full guideline ..................................................................................................................................... 13
5.2 Information for the public................................................................................................................... 13
6 Related NICE guidance............................................................................................................. 14
Published................................................................................................................................................. 14
7 Updating the guideline............................................................................................................... 15
Appendix A: The Guideline Development Group and the Short Clinical Guidelines Technical
Team............................................................................................................................................. 16
Guideline Development Group................................................................................................................ 16
Short Clinical Guidelines Technical Team .............................................................................................. 17
Appendix B: The Guideline Review Panel.................................................................................... 18
About this guideline ...................................................................................................................... 19
NICE 2010. All rights reserved. Last modified August 2010 Page 2 of 20
Introduction
Barrett's oesophagus develops as a consequence of chronic gastro-oesophageal reflux disease.
It is characterised by abnormal changes in the oesophageal lining that may, in some patients,
become dysplastic and lead to oesophageal cancer. Oesophagectomy (surgical removal of the
oesophagus) is the standard NHS treatment for high-grade dysplastic Barrett's oesophagus or
intramucosal cancer (including T1a); however, it is associated with significant mortality and
morbidity. Consequently less invasive surgical techniques, such as endoscopic mucosal
resection, and ablative treatments have been developed and are being used as alternatives for
patients who are unsuitable for surgery or who express a preference for less invasive options.
However, in the past there has been uncertainty whether ablative therapy for Barrett's
oesophagus is both clinically and cost effective compared with other management options.
Radiofrequency ablation is one of the ablative therapies currently being used. This has a
standard depth of ablation that is set by the manufacturer. Photodynamic therapy has a greater
depth of ablation than radiofrequency ablation, irrespective of the photosensitiser used (although
only one photosensitiser (porfirmer sodium) is presently licensed in the UK). However greater
depth of ablation is associated with higher rate of complications but clinicians do not control the
depth and is dependent on the ablative therapy used.
Previously no evidence-based guideline has addressed the use of ablative therapies for the
treatment of Barrett's oesophagus in England and Wales, which may lead to variation in practice.
This clinical guideline covers the use of ablative therapies (argon plasma coagulation, laser
ablation, multipolar electrocoagulation, radiofrequency ablation and photodynamic therapy) and
endoscopic mucosal resection compared with oesophageal surgery, and surveillance with
proton-pump inhibitors for treating Barrett's oesophagus with high-grade dysplasia or with early
intramucosal cancer in adults (18 years and older) in secondary care.
Patient-centred care
This guideline offers best practice advice on the care of adults with a diagnosis of Barrett's
oesophagus with high-grade dysplasia or with intramucosal cancer.
Treatment and care should take into account patients' needs and preferences. People with a
diagnosis of Barrett's oesophagus with high-grade dysplasia or with intramucosal cancer should
have the opportunity to make informed decisions about their care and treatment, in partnership
with their healthcare professionals. If patients do not have the capacity to make decisions,
healthcare professionals should follow the Department of Health's advice on consent and the
code of practice that accompanies the Mental Capacity Act. In Wales, healthcare professionals
should follow advice on consent from the Welsh Government.
Good communication between healthcare professionals and patients is essential. It should be
supported by evidence-based written information tailored to the patient's needs. Treatment and
care, and the information patients are given about it, should be culturally appropriate. It should
also be accessible to people with additional needs such as physical, sensory or learning
disabilities, and to people who do not speak or read English.
If the patient agrees, families and carers should have the opportunity to be involved in decisions
about treatment and care.
Families and carers should also be given the information and support they need.
1 Guidance
The following guidance is based on the best available evidence. The full guideline gives details
of the methods and the evidence used to develop the guidance.
For the purposes of this guideline, the term 'endoscopic mucosal resection' is used
interchangeably with 'endoscopic resection'.
1.1 List of all recommendations
Before considering endoscopic therapy as an alternative to surgery, a confirmed diagnosis of
high-grade dysplasia or intramucosal cancer in Barrett's oesophagus should be agreed by a
designated specialist multidisciplinary team for oesophago-gastric cancer.
Key principles of care
1.1.1 All treatments for high-grade dysplasia and intramucosal cancer in Barrett's
oesophagus should be performed by specialist oesophago-gastric cancer
teams with the experience and facilities to deliver the treatments
recommended in this guideline.
Endoscopic therapies
1.1.2 Consider offering endoscopic therapy as an alternative to oesophagectomy to
people with high-grade dysplasia and intramucosal cancer (T1a), taking into
account individual patient preferences and general health. Endoscopic therapy
is particularly suitable for patients who are considered unsuitable for surgery or
who do not wish to undergo oesophagectomy.
Endoscopic mucosal resection
1.1.3 Consider using endoscopic mucosal resection alone to treat localised lesions.
1.1.4 Use circumferential endoscopic mucosal resection with care because of the
high incidence of stricture formation.
1.1.5 If residual or recurrent disease is suspected, consider additional or repeated
therapy with appropriate follow-up using:
endoscopic mucosal resection with further pathological assessment or
ablative therapy (radiofrequency ablation or photodynamic therapy) or
endoscopic mucosal resection and ablative therapy (radiofrequency ablation, argon
plasma coagulation or photodynamic therapy).
Ablative therapies
1.1.6 Consider using radiofrequency ablation alone or photodynamic therapy alone
for flat high-grade dysplasia, taking into account the evidence of their long-term
efficacy, cost and complication rates.
[1]
1.1.7 Do not use argon plasma coagulation, laser ablation or multipolar
electrocoagulation alone, or in combination with each other, unless as part of a
clinical trial.
Endoscopic mucosal resection in combination with ablative therapies
1.1.8 If using endoscopic mucosal resection, consider following with an additional
ablative therapy (radiofrequency ablation, argon plasma coagulation or
photodynamic therapy) to completely remove residual flat dysplasia, taking into
consideration the side-effect profiles
[1]
.
Patient and carer support and information
1.1.9 Give patients verbal and written information about their diagnosis, available
treatments, patient support groups and the uncertainty of the long-term
outcomes of ablative therapies. Give patients time to consider this information
when making decisions about their care.
1.1.10 Discuss the multidisciplinary team's views on the range of appropriate
treatments with the patient.
1.1.11 Offer patients the opportunity to see the same specialist healthcare team more
than once to agree treatment.
1.1.12 Advise patients who have endoscopic therapy that they will need lifelong care
and repeated endoscopies.
[1]
Recommendation linked to IPG344 and IPG350.
2 Notes on the scope of the guidance
NICE guidelines are developed in accordance with a scope that defines what the guideline will
and will not cover. The scope of this guideline is available from our website click on 'How this
guidance was developed'.
3 Implementation
NICE has developed tools to help organisations implement this guidance.
4 Research recommendations
We have made the following recommendations for research, based on our review of evidence, to
improve NICE guidance in the future.
This guideline focuses on the use of ablative and excisional therapies to treat high-grade
dysplasia or intramucosal cancer in patients with Barrett's oesophagus. Therefore, the natural
history of Barrett's oesophagus, including oesophageal reflux disease, diagnosis and
assessment, and progression to cancer was not reviewed systematically. The Guideline
Development Group noted that treatment should only be considered after a confirmed diagnosis
and full assessment, and they acknowledged that research to support diagnosis and prognosis
was needed. The research recommendations below focus on treatment-related questions.
4.1 Progression to dysplasia
What is the likelihood of Barrett's oesophagus progressing to dysplasia and cancer? What are
the significant influencing factors?
Why this is important
Surgical treatment of high-grade dysplasia is the most effective method of treatment; however,
there are significant but rare adverse effects. Ablative and excisional therapies are also
successful but have an increased risk of recurrence. It is therefore important to identify patients
with the highest risk of developing high-grade dysplasia, both before and after surgery, or
ablative and excisional therapies. Long-term observational studies are needed to identify the risk
of progression and predictive factors (for example age, sex, extent or distribution of disease, or
previous treatments).
4.2 Markers of treatment success
Do anatomical, pathological and molecular markers indicate successful ablation of Barrett's
oesophagus and/or the risk of recurrence of high-grade dysplasia after ablative and excisional
treatment?
High-grade dysplasia in Barrett's oesophagus can recur after ablative and excisional therapies;
however, it is not known if there are anatomical, pathological and molecular markers associated
with the success of treatment or recurrence of high-grade dysplasia. Studies to identify markers
associated with long-term treatment success are needed.
4.3 Effectiveness of treatment
What is the effectiveness of ablative and excisional therapies for the treatment of high-grade
dysplasia or intramucosal cancer in Barrett's oesophagus?
Many cases were reviewed for this guideline; however, high quality evidence from randomised
clinical trials on the benefit of ablative and excisional therapies was lacking. Randomised
controlled trials (or well designed studies with a follow-up of at least 5 years or a central register)
of ablative and excisional therapies compared with surgery, and compared with other ablative
and excisional therapies are required to determine the relative benefits, costs, and impact on
quality of life.
4.4 Follow-up after treatment
What is the most appropriate process of follow-up after the treatment of high-grade dysplasia or
intramucosal cancer in Barrett's oesophagus?
Barrett's oesophagus can recur after ablative and excisional therapies. Evidence for the most
appropriate follow-up is lacking so research should establish how patients should be monitored
after ablative and excisional therapies. This should include randomised controlled trials (with a
follow-up of at least 5 years) to evaluate the effectiveness and optimal timing of different follow-
up approaches such as universal surveillance, endoscopy if symptoms recur.
4.5 Information needs
What are the information needs of patients considering treatment for high-grade dysplasia or
intramucosal cancer in Barrett's oesophagus?
Patients with Barrett's oesophagus deciding on the treatment of high-grade dysplasia or
intramucosal cancer need information to make an informed choice. Substantial literature exists
concerning their general information needs, but there is very little relating to the point of
treatment choice.
Research is required into the delivery of information to patients who are considering ablative and
excisional and other treatments for high-grade dysplasia in Barrett's oesophagus. This should
include randomised controlled trials of different methods to support shared decision-making, with
a process evaluation to identify barriers and facilitators for both patients and healthcare
professionals.
5 Other versions of this guideline
5.1 Full guideline
The full guideline, 'Barrett's oesophagus: Ablative therapy for the treatment of Barrett's
oesophagus', contains details of the methods and evidence used to develop the guideline.
5.2 Information for the public
NICE has produced information for the public explaining this guideline.
We encourage NHS and voluntary sector organisations to use text from this information in their
own materials about Barrett's oesophagus.
6 Related NICE guidance
Published
Endoscopic submucosal dissection (ESD) of oesophageal dysplasia and neoplasia. NICE
interventional procedure guidance 355 (2010).
Photodynamic therapy for Barrett's oesophagus. NICE interventional procedure guidance
350 (2010).
Epithelial radiofrequency ablation for Barrett's oesophagus. NICE interventional procedure
guidance 344 (2010).
Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. NICE
Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for
the treatment of gastro-oesophageal reflux disease. NICE interventional procedure guidance
222 (2007).
Photo-dynamic therapy for early oesophageal cancer. NICE interventional procedure
guidance 200 (2006).
Thoracoscopically assisted oesophagectomy. NICE interventional procedure guidance 189
(2006). [Replaced by 'Minimally invasive oesophagectomy' (NICE interventional procedure
guidance 407) (2011)]
Endoluminal gastroplication for gastro-oesophageal reflux disease. NICE interventional
procedure guidance 115 (2005). [Replaced by 'Endoluminal gastroplication for gastro-
oesophageal reflux disease' (NICE interventional procedure guidance 404) (2011)].
Dyspepsia: managing dyspepsia in adults in primary care. NICE clinical guideline 17 (2004).
Endoscopic injection of bulking agents for gastro-oesophageal reflux disease. NICE
7 Updating the guideline
NICE clinical guidelines are updated so that recommendations take into account important new
information. New evidence is checked 3 years after publication, and healthcare professionals
and patients are asked for their views; we use this information to decide whether all or part of a
guideline needs updating. If important new evidence is published at other times, we may decide
to do a more rapid update of some recommendations. Please see our website for information
about updating the guideline.
Appendix A: The Guideline Development Group and the
Short Clinical Guidelines Technical Team
Guideline Development Group
Damien Longson (Chair)
Consultant Liaison Psychiatrist, Manchester Mental Health & Social Care Trust, Manchester
Hugh Barr
Professor of Upper Gastrointestinal Surgery, Gloucestershire Hospitals NHS Trust, Gloucester
Pradeep Bhandari
Consultant Gastroenterologist, Portsmouth Hospital NHS Trust, Portsmouth
Ricky Forbes-Young
Advanced Nurse Practitioner, Western General Hospital, Edinburgh
Janusz Jankowski
Professor of Gastroenterology & Endoscopy, Leicester Hospitals NHS Trust, Leicester
Laurence Lovat
Consultant Gastroenterologist & Senior Lecturer in Laser Medicine, UCL Hospitals NHS Trust,
London
Robert Mason
Consultant Upper Gastrointestinal Surgeon, Guy's and St Thomas' Hospitals, London
Mimi McCord
Patient/Carer member
Andrea Nicholls
Advanced Nurse Practitioner, Leeds Teaching Hospitals Trust, Leeds
David Poller
Consultant Pathologist, Queen Alexandra Hospital, Portsmouth
Short Clinical Guidelines Technical Team
A short clinical guidelines technical team was responsible for this guideline throughout its
development. It prepared information for the Guideline Development Group, drafted the guideline
and responded to consultation comments. The following NICE employees made up the technical
team for this guideline.
Kathryn Chamberlain
Project Manager
Nicole Elliott
Associate Director
Prashanth Kandaswamy
Technical Adviser (Health Economics)
Caroline Keir
Guideline Commissioning Manager
Hanna Lewin
Information Specialist
Jonathan Nyong
Assistant Technical Analyst
Beth Shaw
Technical Adviser
Tarang Sharma
Technical Analyst
Nicholas Staples
Guidelines Coordinator
Appendix B: The Guideline Review Panel
The Guideline Review Panel is an independent panel that oversees the development of the
guideline and takes responsibility for monitoring adherence to NICE guideline development
processes. In particular, the panel ensures that stakeholder comments have been adequately
considered and responded to. The panel includes members from the following perspectives:
primary care, secondary care, lay, public health and industry.
Dr Robert Walker (Chair for scope sign-off)
General Practitioner, Workington
Professor Mike Drummond (stand in Chair for draft guideline sign-off)
Director, Centre for Health Economics, University of York
Mr Robin Beal
Consultant in Accident and Emergency Medicine, Isle of Wight
Mrs Ailsa Donnelly
Lay member
Mrs Sarah Fishburn
Lay member
Dr John Harley
Clinical Governance and Prescribing Lead and General Practitioner, North Tees PCT
Dr Mark Hill
Head of Medical Affairs, Novartis Pharmaceuticals UK Ltd
About this guideline
NICE clinical guidelines are recommendations about the treatment and care of people with
specific diseases and conditions in the NHS in England and Wales.
The guideline was developed by the Short Clinical Guidelines Technical Team. The team worked
with a group of healthcare professionals (including consultants, GPs and nurses), patients and
carers, and technical staff, who reviewed the evidence and drafted the recommendations. The
recommendations were finalised after public consultation.
The methods and processes for developing NICE clinical guidelines are described in The
guidelines manual. This guideline was developed using the short clinical guideline process.
We have produced information for the public explaining this guideline. Tools to help you put the
guideline into practice and information about the evidence it is based on are also available.
Changes after publication
20 December 2011: Layout changed to match other NICE guidelines.
May 2013: Minor maintenance.
Your responsibility
This guidance represents the view of NICE, which was arrived at after careful consideration of
the evidence available. Healthcare professionals are expected to take it fully into account when
exercising their clinical judgement. However, the guidance does not override the individual
responsibility of healthcare professionals to make decisions appropriate to the circumstances of
the individual patient, in consultation with the patient and/or guardian or carer, and informed by
the summary of product characteristics of any drugs they are considering.
Implementation of this guidance is the responsibility of local commissioners and/or providers.
Commissioners and providers are reminded that it is their responsibility to implement the
guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have
regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a
way that would be inconsistent with compliance with those duties.
Copyright
National Institute for Health and Clinical Excellence 2010. All rights reserved. NICE copyright
material can be downloaded for private research and study, and may be reproduced for
educational and not-for-profit purposes. No reproduction by or for commercial organisations, or
for commercial purposes, is allowed without the written permission of NICE.
Contact NICE
National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT
www.nice.org.uk
[email protected]
0845 033 7780

Barrett's Oesophagus

Uploaded by

Copyright:

Available Formats

Barrett's Oesophagus

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Barrett's Oesophagus

Uploaded by

Copyright:

Available Formats

Barrett's oesophagus

Ablative therapy for the treatment of Barrett's

You might also like